Physician profile
Mark R Johnson
NPI 1043202393
$814.30
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2020: $197 · 2021: $261 · 2022: $126.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $278.54 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $189.62 | 2020-2022 | |
| Amarin Pharma, INC. | $104.55 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $70.50 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $50.02 | 2021 | |
| Xeris Pharmaceuticals, INC. | $33.64 | 2022 | |
| Siemens Medical Solutions USA, INC. | $32.10 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.99 | 2022 | |
| Medtronic, INC. | $20.19 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.15 | 2020 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.